Clinical Pharmacogenomic of Vildagliptin in Egyptian Patients with Insulin Resistance
Main Article Content
Keywords
obesity, GLP1R gene, vildagliptin, insulin resistant
Abstract
Background: Pharmacogenomics is the study of how genes affect a person’s response to drugs. Insulin resistance is a pathological state in which a given insulin concentration produces a less-than-expected biological effect.
Aim: This study aimed to investigate the association of rs6923761 variants in GLP 1R gene response to vildagliptin after 6 months’ follow-up in Egyptian patients with insulin resistance (IR).
References
2019. . [Online]. Available:
https://ghr.nlm.nih.gov/primer/genomicresearch/pharmacogenomics.
[2]
[3]
[4]
C. A. R.-G. a. J. O.-R. Gutierrez-Rodelo, "[Molecular Mechanisms of Insulin
Resistance," An Update., pp. (0016-3813)., ..
S. T. Olatunbosun, "Endocrinology Service, SAMMC/59th Medical Wing and
Uniformed Services University of the Health Sciences, F Edward Hebert School
of Medicine.," 2019.
H. W. G. A. Omar G, "Association among insulin receptor substrate1 genetic
polymorphism, sulfonylurea therapeutic efficacy, and insulin resistance in patients
with type 2 diabetes mellitus," Journal of Medicine in Scientific Research,, Vols.
4(3),, p. 196, 2021.
[5] P. H. K. O. C. E. W. H. L. Y. Han E, "genetic variant in GLP1R is associated with
response to DPP-4 inhibitors in patients with type 2 diabetes.," Medicine., p. 95:
e5155. 10.1097/MD.0000000000005155., 2016.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.